Skip to main content
. 2020 Apr 10;10:6169. doi: 10.1038/s41598-020-63263-6

Figure 1.

Figure 1

TRILOGY-ACS analysis cohort. Our primary analysis cohort was derived from patients included in the TRILOGY-ACS and subsequent Advanced Biomarker Sub-study. The primary TRILOGY-ACS trial found no difference in outcomes (CV death/MI/stroke) between prasugrel vs. clopidogrel treatment groups. Further details of the TRILOGY-ACS and the Advanced Biomarker Sub-study are included in the Supplemental Methods.